Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saracatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 18/20 | 1.00 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | CSK | P41240 | 2/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saracatinib SCHEMBL29380648 | 1.00 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL29487213 | 1.00 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL41547 | 1.00 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL4255230 | 0.99 | SRC (0.99) | SRCKDREGFRLCKYES1 | |
| SCHEMBL3203253 | 0.96 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| SCHEMBL29272754 | 0.96 | SRC (0.92) | SRCKDREGFRLCKYES1 | |
| SCHEMBL3202847 | 0.94 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL4260314 | 0.94 | SRC (0.89) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL29375375 | 0.94 | SRC (0.89) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL4260310 | 0.94 | SRC (0.89) | SRCKDREGFRLCKYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2321 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| WO-2026043541-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TUFTS MEDICAL CENTER, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-20260049111-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | MULTIVIR INC. (US) | 2026-02-19 | — | — | US | claimed |
| US-20250360129-A1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2025-11-27 | — | — | US | claimed |
| WO-2025188678-A9 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4649139-A1 | METHODS FOR EXPANDING IMMUNE CELLS AND RELATED COMPOSITIONS AND USES THEREOF | Nkarta, Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| EP-4636093-A1 | TARGETING MAPK-ERK PATHWAY FOR ENHANCING NUCLEIC ACID DELIVERY | Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (DE) | 2025-10-22 | — | — | EP | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| EP-3964214-A1 | MODULATORS OF AIRWAY BASAL CELLS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-03-09 | — | — | EP | claimed |
| US-20220062269-A1 | MODULATORS OF AIRWAY BASAL CELLS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-03-03 | — | — | US | claimed |
| WO-2022045976-A1 | METHOD OF MODULATING SENSITIVITY TO TYROSINE KINASE INHIBITOR | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2022-03-03 | — | — | WO | claimed |
| WO-2022038038-A2 | MEANS FOR THE THERAPY OF TUMOR DISEASES | EPO EXPERIMENTELLE PHARMAKOLOGIE & ONKOLOGIE BERLIN-BUCH GMBH (DE) | 2022-02-24 | — | — | WO | claimed |
| WO-2022035723-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20220040181-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-10 | — | — | US | claimed |
| US-11241434-B2 | Compositions and methods for improving cognition in a subject | Yale Uninversity (US) | 2022-02-08 | — | — | US | claimed |